Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
MeSH Number(s)
D27.505.519.186.071.202.370
D27.505.519.389.370
D27.505.954.557.500.202.370
Concept/Terms
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Reductase Inhibitors, HMG-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Harvard Catalyst Profiles by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 1 | 1 |
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 3 | 4 |
| 1995 | 0 | 1 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 7 | 1 | 8 |
| 1999 | 3 | 1 | 4 |
| 2000 | 13 | 6 | 19 |
| 2001 | 16 | 4 | 20 |
| 2002 | 30 | 4 | 34 |
| 2003 | 29 | 12 | 41 |
| 2004 | 32 | 10 | 42 |
| 2005 | 48 | 4 | 52 |
| 2006 | 45 | 25 | 70 |
| 2007 | 50 | 15 | 65 |
| 2008 | 41 | 26 | 67 |
| 2009 | 50 | 12 | 62 |
| 2010 | 57 | 19 | 76 |
| 2011 | 71 | 27 | 98 |
| 2012 | 68 | 21 | 89 |
| 2013 | 74 | 22 | 96 |
| 2014 | 91 | 25 | 116 |
| 2015 | 106 | 30 | 136 |
| 2016 | 61 | 40 | 101 |
| 2017 | 92 | 29 | 121 |
| 2018 | 87 | 26 | 113 |
| 2019 | 64 | 34 | 98 |
| 2020 | 35 | 18 | 53 |
| 2021 | 1 | 0 | 1 |
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun. 2021 02 26; 12(1):1325.
-
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.
-
Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial. JAMA Netw Open. 2020 12 01; 3(12):e2027092.
-
New Statin Use and Mortality in Older Veterans-Reply. JAMA. 2020 11 10; 324(18):1908-1909.
-
Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease. BMC Med Inform Decis Mak. 2020 11 04; 20(1):288.
-
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262.
-
Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart J. 2021 02; 232:105-115.
-
Effect of Patient Financial Incentives on Statin Adherence and Lipid Control: A Randomized Clinical Trial. JAMA Netw Open. 2020 10 01; 3(10):e2019429.
-
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res. 2020 12; 196:382-394.
-
Relation of Absence of Coronary Artery Calcium to Cardiovascular Disease Mortality Risk Among Individuals Meeting Criteria for Statin Therapy According to the 2018/2019 ACC/AHA Guidelines. Am J Cardiol. 2020 12 01; 136:49-55.